# Dean G Brown

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5808127/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 39<br>papers | 2,492<br>citations | 304743<br>22<br>h-index | 302126<br>39<br>g-index |
| 42<br>all docs | 42<br>docs citations | 42<br>times ranked | 4116<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A Decade of FDA-Approved Drugs (2010â€“2019): Trends and Future Directions. Journal of Medicinal Chemistry, 2021, 64, 2312-2338. | 6.4 | 145 |
| 2 | A Survey of the Clinical Pipeline in Neuroscience. Bioorganic and Medicinal Chemistry Letters, 2021, 56, 128482. | 2.2 | 0 |
| 3 | Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research. Journal of Medicinal Chemistry, 2020, 63, 1823-1840. | 6.4 | 33 |
| 4 | Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies. Journal of Medicinal Chemistry, 2020, 63, 6251-6275. | 6.4 | 12 |
| 5 | Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126942. | 2.2 | 31 |
| 6 | The clinical trial landscape in amyotrophic lateral sclerosisâ€”Past, present, and future. Medicinal Research Reviews, 2020, 40, 1352-1384. | 10.5 | 61 |
| 7 | CETSA beyond Soluble Targets: a Broad Application to Multipass Transmembrane Proteins. ACS Chemical Biology, 2019, 14, 1913-1920. | 3.4 | 55 |
| 8 | Discovery of Ligand-Efficient Scaffolds for the Design of Novel Trichomonas vaginalis Uridine Nucleoside Ribohydrolase Inhibitors Using Fragment Screening. ACS Omega, 2019, 4, 16226-16232. | 3.5 | 5 |
| 9 | Ligand-Efficient Inhibitors of Trichomonas vaginalis Adenosine/Guanosine Preferring Nucleoside Ribohydrolase. ACS Infectious Diseases, 2019, 5, 345-352. | 3.8 | 8 |
| 10 | Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1962-1967. | 2.2 | 7 |
| 11 | Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery, 2018, 17, 167-181. | 46.4 | 294 |
| 12 | Where Do Recent Small Molecule Clinical Development Candidates Come From?. Journal of Medicinal Chemistry, 2018, 61, 9442-9468. | 6.4 | 131 |
| 13 | Structural insight into allosteric modulation of protease-activated receptor 2. Nature, 2017, 545, 112-115. | 27.8 | 192 |
| 14 | Drug discovery strategies to outer membrane targets in Gram-negative pathogens. Bioorganic and Medicinal Chemistry, 2016, 24, 6320-6331. | 3.0 | 22 |
| 15 | Design and synthesis of peptide-based macrocyclic cyclophilin inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5304-5307. | 2.2 | 4 |
| 16 | Discovery and Preclinical Validation of [11C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. ACS Chemical Neuroscience, 2016, 7, 177-184. | 3.5 | 7 |
| 17 | Stuck in a rut with old chemistry. Drug Discovery Today, 2016, 21, 701-703. | 6.4 | 11 |
| 18 | Understanding Our Love Affair with p-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection. Journal of Medicinal Chemistry, 2015, 58, 2390-2405. | 6.4 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | ESKAPEing the labyrinth of antibacterial discovery. Nature Reviews Drug Discovery, 2015, 14, 529-542. | 46.4 | 498 |
| 20 | Novel Antibacterial Targets and Compounds Revealed by a High-Throughput Cell Wall Reporter Assay. Journal of Bacteriology, 2015, 197, 1726-1734. | 2.2 | 79 |
| 21 | New natural products as new leads for antibacterial drug discovery. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 413-418. | 2.2 | 162 |
| 22 | Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition. Journal of Medicinal Chemistry, 2014, 57, 733-758. | 6.4 | 22 |
| 23 | Trends and Exceptions of Physical Properties on Antibacterial Activity for Gram-Positive and Gram-Negative Pathogens. Journal of Medicinal Chemistry, 2014, 57, 10144-10161. | 6.4 | 196 |
| 24 | Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6789-6793. | 2.2 | 38 |
| 25 | Azepines and Piperidines with Dual Norepinephrine Dopamine Uptake Inhibition and Antidepressant Activity. ACS Medicinal Chemistry Letters, 2013, 4, 46-51. | 2.8 | 24 |
| 26 | Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1402-1406. | 2.2 | 28 |
| 27 | 2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3399-3403. | 2.2 | 24 |
| 28 | SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5405-5410. | 2.2 | 17 |
| 29 | Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5847-5852. | 2.2 | 22 |
| 30 | 4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7381-7384. | 2.2 | 26 |
| 31 | In Vitro Metabolism Studies of Nomifensine Monooxygenation Pathways: Metabolite Identification, Reaction Phenotyping, and Bioactivation Mechanism. Drug Metabolism and Disposition, 2010, 38, 1767-1778. | 3.3 | 21 |
| 32 | Identification of Multiple Glutathione Conjugates of 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline maleate (Nomifensine) in Liver Microsomes and Hepatocyte Preparations: Evidence of the Bioactivation of Nomifensine. Drug Metabolism and Disposition, 2010, 38, 46-60. | 3.3 | 14 |
| 33 | Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behavioural Brain Research, 2010, 212, 168-173. | 2.2 | 64 |
| 34 | Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain. Journal of Medicinal Chemistry, 2007, 50, 3113-3131. | 6.4 | 14 |
| 35 | N-Methyl-D-Aspartate Receptor (NMDA) Antagonists as Potential Pain Therapeutics. Current Topics in Medicinal Chemistry, 2006, 6, 749-770. | 2.1 | 37 |
| 36 | Synthesis of 7-Chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]pyridazino [4,5-b]quinoline-1,4,10(5H)-triones as NMDA Glycine-Site Antagonists.. ChemInform, 2004, 35, no. | 0.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Synthesis of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5- b ]quinoline-1,4,10(5 H )-triones as NMDA glycine-site antagonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3553-3556. | 2.2 | 20 |
| 38 | Synthesis of Azulenone Skeletons by Reaction of 2-Phenyl-2-acylketenes [RCO(Ph)CCO] with Alkynyl Ethers:â€‰ Mechanistic Aspects and Further Transformations. Journal of Organic Chemistry, 1998, 63, 1630-1636. | 3.2 | 23 |
| 39 | A Convenient Synthesis of Dimethyl (Diazomethyl)phosphonate (Seyferth/Gilbert Reagent). Journal of Organic Chemistry, 1996, 61, 2540-2541. | 3.2 | 84 |